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Abstract
Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential.
This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the
management of HAE. In the development of this update and revision of the guideline, an international expert
panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and
consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and
revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies.
The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will
assist them in making rational decisions in the management of HAE with deficient C1-inhibitor (type 1) and HAE
with dysfunctional C1-inhibitor (type 2). The key clinical questions covered by these recommendations are: 1) How
should HAE-1/2 be defined and classified?, 2) How should HAE-1/2 be diagnosed?, 3) Should HAE-1/2 patients
receive prophylactic and/or on-demand treatment and what treatment options should be used?, 4) Should HAE-1/2
management be different for special HAE-1/2 patient groups such as pregnant/lactating women or children?, and
5) Should HAE-1/2 management incorporate self-administration of therapies and patient support measures?
This article is co-published with permission in Allergy and the World Allergy Organization Journal.
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Introduction
Hereditary angioedema (HAE) is a rare disease and a ser-
ious health problem, globally and for affected patients and
their families. The pathophysiological background is pri-
marily a vascular reaction to an overshooting local pro-
duction of bradykinin. Evidence-based recommendations
are needed to inform and guide clinical decision makers.
This is the first revision and update of the global guideline
for the diagnosis and management of HAE [1]. It was
developed by the World Allergy Organization (WAO) in
collaboration with the European Academy of Allergy and
Clinical Immunology (EAACI). This revised and updated
WAO/EAACI guideline on the diagnosis and manage-
ment of HAE differs from previous consensus reports and
position papers [2–16]. It results from a complete review
of the underlying evidence based on systematic and trans-
parent assessments of the quality of this evidence. We
used an approach oriented along the Grading of Recom-
mendations Assessment, Development and Evaluation
(GRADE) approach for the revision and update of the rec-
ommendations provided by this guideline [17]. GRADE is
recommended by the World Health Organization (WHO)
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and takes into account that evidence alone is insufficient,
and that values and preferences, clinical circumstances as
well as clinical expertise inevitably influence decisions.
During the planning of the WAO HAE International
Guideline, Dr. Richard Lockey, then President of the
WAO, and Dr. Timothy Craig, Chair of the steering
committee, requested nominations from WAO Affiliated
Allergy and Immunology Associations to appoint mem-
bers to the steering committee. For this update and revi-
sion of the guideline, the guideline’s expert panel and
author group was complemented by additional HAE ex-
perts to account for the global reach of the guideline.
In the development of this update and revision of the
guideline, working groups were assigned to review and
assess the evidence available to answer the questions, for
which the guideline provides recommendations ([1]),
and to raise new clinical questions to be addressed by
the guideline [18]. Based on the assessment of the evi-
dence the panel members, in a consensus conference at
the EAACI annual meeting in June 2016 in Vienna,
Austria, developed the following recommendations.
Using the approach outlined below, recommendations
made are strong or weak. Strong recommendations indi-
cate that most physicians would want and only few
would not want the recommended course of action, that
adherence to the recommendation in clinical practice
could be used as a quality criterion and that the recom-
mendation can be adapted as policy in most situations
and countries. Weak recommendations should be inter-
preted to indicate that most but not all physicians would
want the suggested course of action, that in clinical prac-
tice, different choices will be appropriate for individual
patients, and that policy making will require substantial
debate and the involvement of various stakeholders [19].
Understanding the interpretation of these two grades of
strengths of recommendations (either strong or weak/
conditional) is essential for clinical decision-making.
This guideline is unique in that global involvement
was ensured by the participation of international experts
from many different countries. Most of these experts
were nominated by Allergy and Immunology Associa-
tions of different countries affiliated to the WAO.
The goal of this guideline is to provide clinicians and
their patients with guidance that will assist them in mak-
ing rational decisions in the management of HAE with de-
ficient C1-inhibitor (type 1) and HAE with dysfunctional
C1-inhibitor (type 2, in this consensus the abbreviation
HAE-1/2 will be utilized). To this end, 20 recommenda-
tions (numbered and given in framed boxes) were devel-
oped. The key clinical questions covered by these
recommendations are: 1) How should HAE-1/2 be defined
and classified?, 2) How should HAE-1/2 be diagnosed?, 3)
Should HAE-1/2 patients receive prophylactic and/or on-
demand treatment and what treatment options should be
used?, 4) Should HAE-1/2 management be different for
special HAE-1/2 patient groups such as pregnant/lactating
women or children?, and 5) Should HAE-1/2 management
incorporate self-administration of therapies and patient
support measures?
It is important to mention that the array of available
therapies for HAE patients is limited in certain areas of
the world, but the intent of this guideline is to help
change this and to encourage the use of recommended
therapies for all patients.
Methods
Nomination of experts
Physicians were nominated to the expert panel and group
of authors by the steering committee nominated by WAO
and/or EAACI. At least one of the following criteria had
to be fulfilled: 1) Extensive clinical experience in the treat-
ment of HAE, 2) Relevant publications in the field of
HAE, 3) Relevant experience in evidence-based medicine.
Emphasis was placed on selecting a representative panel
of experts from throughout the world to ensure global ex-
pertise. In addition, the WAO requested a representative
from the international HAE patient association (HAEi) to
participate as an author group member. One patient rep-
resentative was nominated by HAEi and participated in
the process (selection of key questions).
Funding and support
Funding of the development of this update and revision of
the guideline including for the Guideline Conference was
done through the WAO and the EAACI. No company or
company representative was present during the meeting,
had input into the manuscript, or was allowed to provide
feedback. The pharmaceutical companies were not
allowed to view the document before publication. This
was essential to prevent bias and real or perceived com-
mercial influence on the outcomes. All participants were
required to submit conflict of interest statements to par-
ticipate as expert panel members and authors.
Selection of key questions, wording of recommendations,
and literature research
All authors were assigned to one of 5 working groups: 1)
diagnostic work-up, 2) on demand therapy, 3) prophylaxis,
4) special populations, 5) clinical management of HAE-1/
2. First, the teams were asked to review the existing rec-
ommendations from the WAO/EAACI guideline 2012 [1]
in their subject area and to assess these recommendations
for accuracy and relevance to current practice. The groups
were asked to critically review the wording and to reword
if necessary. A standardized wording was used to phrase
the recommendations (Table 1).
Second, the teams were asked to consider if new rec-
ommendations were needed or useful and agree on the
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generation of new recommendations and wording.
Third, the teams were prompted to search the literature
(database MEDLINE and COCHRANE) that supports
each recommendation.
For the update and revision of recommendations from
the previous version of the guideline, an incremental
systematic search from September 2010 (end of search
of the WAO/EAACI guideline 2012 [1]) to current
(2016/05/31) was performed (Table 2). For new and add-
itional recommendations, a complete search from 1985
to current (2016/05/31) was performed.
Fourth, the teams evaluated the publications found
in their search using a standardized worksheet (Figs. 1
and 2). Each manuscript/trial included in the guide-
line was evaluated with regard to its methodological
quality and assigned a grade of evidence according to
the grading system used in the previous version of
this guideline (Table 3).
Consensus conference, drafting of the manuscript, and
review by the review board
The open consensus conference was held in Vienna on
11th of June 2016. Based on the assessment of the evi-
dence, the expert panel reviewed the existing recommen-
dations and developed new recommendations. The expert
teams were asked to present a summary of the evidence
on each revision and update of existing recommendations
as well as on each new recommendation to all conference
participants and to give their assessment of the quality of
evidence expressed by the “evidence grade” (Table 3).
During the consensus conference, the nominal group
technique was used as the formal consensus method-
ology [20]. All expert panel members were entitled to
vote on the recommendations. The nominal group tech-
nique was moderated by Alexander Nast, MD, certified
moderator for the German Association of Scientific
Medical Societies (AWMF). All consented recommenda-
tions are highlighted throughout the guideline document
(grey boxes). In order to avoid ambiguity, a standardized
language was used to classify the direction and strength
of each recommendation (Table 1).
The participants of the consensus conference were
asked to discuss and vote whether they agreed with
recommendations and other specific parts of the
text. In statements not receiving ≥90% approval dur-
ing the first voting, the recommendation was re-
discussed, rephrased, and voted on and passed by
majority vote. This was a minimum of ≥75% agree-
ment unless stated otherwise. All voting results were
documented (% agreement).
International HAE experts (the Review Board Con-
sultation Group) were requested to review the guide-
line and provide feedback and suggestions for
changes. The guideline was then reviewed by the
WAO and EAACI and the other endorsing societies
for content and the document was approved as “The
international WAO/EAACI guideline for the man-
agement of hereditary angioedema – the 2017 revi-
sion and update”.
Definitions, nomenclature, and classification
Angioedema is defined as a vascular reaction of deep der-
mal/subcutaneous tissues or mucosal/submucosal tissues
with localized increased permeability of blood vessels
resulting in tissue swelling [21–25]. Angioedema can be
mediated by bradykinin and/or mast cell-mediators in-
cluding histamine (Tables 4 and 5) [13, 26]. Bradykinin-
mediated angioedema can occur either on a hereditary or
acquired basis, due to a deficiency/defect of C1 inhibitor
(C1-INH) or other mechanisms (Table 4) [27, 28]. Differ-
ent forms of hereditary angioedema (HAE) are currently
recognized and genetically identifiable: 1) HAE due to C1-
INH deficiency (Type 1 HAE, HAE-1), characterized by
low antigenic and functional C1-INH levels; 2) HAE due
to C1-INH dysfunction (Type 2 HAE, HAE-2), character-
ized by normal (or elevated) antigenic but low functional
C1-INH levels [29, 30], 3) HAE with mutation in the F12
gene (HAE-FXII) [31]; 4) HAE with mutation in the
angiopoietin-1 gene (HAE-ANGPTI) [32]; and 5) HAE
with mutation in the plasminogen gene (HAE-PLG) [33].
In addition, some patients have HAE due to unknown
mutations (HAE-UNK). Different forms of HAE with nor-
mal C1-INH (HAE-FXII, HAE-ANGPTI, HAE-PLG,
HAE-UNK) share some clinical features and, possibly,
therapeutic options.
Acquired angioedema with low C1-inhibitor, hence-
forth called AAE-C1-INH, refers to patients with an-
gioedema due to C1-INH deficiency on an acquired
basis (Table 4) [34–36]. There are a variety of ac-
quired types of angioedema not due to C1-INH defi-
ciency, and these may be bradykinin-mediated (e.g.
ACE inhibitor induced angioedema, ACEI-AE) or due
Table 1 Wording of recommendations used in this guideline
Strong recommendation We recommend
Weak recommendation We suggest
Strength of recommendation, standardized wording
Table 2 Example of search strategy and identified hits
incremental search
Step Search terms Hits
1 “Hereditary angioedema” OR “Hereditary angiooedema” OR
“Hereditary angio-oedema” OR “Hereditary angioneurotic
oedema”
OR “Hereditary angioneurotic edema”
2063
2 Limit to yr. = 2010/09/01 - current (2016/05/31) 718
3 Limit to “Clinical Trial” 51
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to mast cell mediators (e.g. urticarial angioedema,
anaphylactic angioedema) [27, 37].
This guideline only refers to HAE-1/2.
Pathophysiology
HAE-1 and HAE-2
HAE-1/2 is a rare autosomal dominant condition affect-
ing an estimated 1 in 50,000 individuals [38, 39] al-
though this may vary in different regions. HAE-1/2 is
caused by one of more than 450 different mutations in
the SERPING1 gene, which codes for C1-INH [40]. In
approximately 20–25% of patients, a de novo mutation
of SERPING1 is responsible for the disease [41, 42].
C1-INH is a serine protease inhibitor (SERPIN) and
the major inhibitor of several complement proteases
(C1r, C1s, and mannose-binding lectin–associated
serine protease [MASP] 1 and 2) and contact-system
proteases (plasma kallikrein and coagulation factor
XIIa) as well as a relatively minor inhibitor of the fi-
brinolytic protease plasmin [43, 44].
The primary mediator of swelling in HAE-1/2 is
bradykinin [28]. Bradykinin is a low molecular
weight nonapeptide, which is generated when active
plasma kallikrein cleaves high molecular weight
kininogen (HMWK). Bradykinin is rapidly metabo-
lized by endogenous metalloproteases including
angiotensin-converting enzyme (ACE) [45]. Plasma
kallikrein is activated from its inactive zymogen pre-
kallikrein by the protease factor XII, which can eas-
ily autoactivate upon contact with negatively-charged
Fig. 1 Literature evaluation form
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surfaces. Both, plasma kallikrein and factor XII are
inhibited by C1-INH. Increased vascular permeability
induced by the liberation of bradykinin in angio-
edema is primarily mediated through the bradykinin
B2 receptor [46–51].
HAE with normal C1 inhibitor
HAE with normal C1-INH (HAE nC1-INH) is a very rare
disease. Its clinical appearance largely resembles that of
HAE-1/2. In a subgroup of patients, HAE nC1-INH is as-
sociated with mutations of the factor XII (FXII-HAE)
gene. Recently, two new mutations in - (ANGPT1) and
plasminogen (PLG) were reported in HAE nC1-INH [32,
33]. However, in most patients with HAE nC1-INH, no
gene mutation can be found, and the pathogenesis
remains to be characterized in detail. However, there is
clinical evidence that bradykinin may play a major role in
some types of HAE nC1-INH, primarily in patients with a
FXII-mutation [52–54]. Although HAE nC1-INH shares
some clinical features and, possibly, therapeutic options
with HAE-1/2, this guideline is for HAE-1/2.
Diagnosis
HAE-1/2 should be suspected when a patient presents with
a history of recurrent angioedema attacks. This suspicion is
further substantiated when patients report: 1) a positive
family history (although this may not be present in up to
25% of patients), 2) onset of symptoms in childhood/ado-
lescence, 3) recurrent and painful abdominal symptoms, 4)
occurrence of upper airway edema, 5) failure to respond to
antihistamines, glucocorticoids, or epinephrine, 6) presence
of prodromal signs or symptoms before swellings, and/or
7) the absence of urticaria (wheals). Suspicion of HAE-1/2
should prompt laboratory investigations to support the
diagnosis of HAE-1/2 (Fig. 2) [5, 7, 13, 55].
Recommendation 1
We recommend that all patients suspected to have HAE-1/2 are
assessed for blood levels of C1-INH function, C1-INH protein, and C4. If
any of the levels are abnormally low, the tests should be repeated to
confirm the diagnosis of HAE-1/2.
Evidence grade: D; Strength of recommendation: Strong, ≥ 90
agreement.
Fig. 2 Diagnostic work up in patients suspected to have HAE. Abbreviations: HAE-1: Hereditary angioedema due to C1-Inhibitor
deficiency; HAE-2: Hereditary angioedema due to C1-Inhibitor dysfunction; AAE-C1-INH: acquired angioedema due to C1-Inhibitor
deficiency; HAE nC1-INH: Hereditary angioedema with normal C1-Inhibitor levels, either due to a mutation in factor XII (FXII)
angiopoetin (ANGPTI) or plasminogen (PLG); ACEI-AE: angiotensin converting enzyme inhibitor-induced angioedema
Table 3 Evidence grades (based on the previous guideline
version [1])
A Randomized, double-blind clinical trial of high quality (for example,
sample-size calculation, flow chart of patient inclusion, intention-to-treat
(ITT) analysis, sufficient sample size)
B Randomized clinical trial of lesser quality (for example, only single-
blind, limited sample size: at least 15 patients per study arm)
C Comparative trial with severe methodological limitations (for example,
not blinded, very small sample size, no randomization) or large
retrospective observational studies.
D Adapted from existing consensus document or statement based on
expert opinion voting during consensus conference
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Measurements of serum/plasma levels of C1-INH
function, C1-INH protein, and C4 are used to diag-
nose HAE-1/2. In HAE-1, which comprises about
85% of patients, both, the concentration and function
of C1-INH are low (Table 4). In HAE-2, C1-INH
concentrations are either normal or elevated, whereas
C1-INH function is reduced. C4 levels are usually
low in HAE-1/2 patients, but its sensitivity and speci-
ficity are limited [56–59]. Abnormal results should be
confirmed. Complement C3 and CH50 levels are
expected to be normal in HAE, and testing is usually
not helpful. Sequencing of the SERPING1 gene can
be supportive in the diagnostic workup of some
HAE-1/2 patients (including prenatal diagnosis); how-
ever, biochemical C1-INH testing is effective and less
expensive than genetic testing [59]. DNA sequencing
may miss mutations such as those creating cryptic
splice sites. Genetic testing may be relevant in par-
ticular cases such as mosaicisms in order to allow for
correct genetic counselling [60].
Differential diagnosis
The differential diagnoses of HAE-1/2 include the other
forms of HAE as mentioned above, AAE-C1-INH,
ACEI-AE, mast cell-mediated angioedema (e.g. angio-
edema in patients with chronic spontaneous urticaria
without wheals, allergic angioedema), and idiopathic an-
gioedema (Table 4). Because the pathophysiology and
the management of these diseases are different from
those of HAE-1/2, it is important to determine the cor-
rect diagnosis [1, 7, 13, 61].
Recurrent mast cell-mediated angioedema (in the
past sometimes referred to as idiopathic angioedema)
is frequently associated with intensely pruritic wheal
and flare skin reactions, (hives), in patients with
chronic spontaneous urticaria (CSU). Some CSU patients
do not show wheals and exclusively develop angioedema.
On the other hand, CSU is a common disease, which can
also affect HAE patients. The occurrence of wheals,
therefore, does not necessarily exclude HAE, and the
absence of wheals does not exclude mast cell-mediated
angioedema [62]. Non-sedating antihistamines, at stan-
dard or higher-than-standard doses, alone or in combi-
nation with omalizumab or immune modulators such
as cyclosporine are capable of preventing wheals and
angioedema in CSU patients [37, 63]. Because mast
cell-mediated angioedema is far more common than
HAE-1/2, on demand therapy with antihistamines and,
if necessary, with epinephrine and corticosteroids, is
indicated when the diagnosis is not yet determined
and the history seems to be inconsistent with HAE
[37, 64, 65].
Angioedema attacks in patients with HAE nC1-INH
and in patients taking ACE inhibitors are thought to be
bradykinin-mediated [66–75].
AAE-C1-INH, i.e. recurrent angioedema due to
aqcuired C1-INH deficiency, occurs less frequently
than HAE-1/2. AAE-C1-INH symptoms are similar to
those of HAE-1/2 and the basic diagnostic laboratory
profile (C1-INH function, C1-INH protein and C4) is
indistinguishable from HAE-1. Differences include
onset at later age, underlying diseases such as lymph-
oma or benign monoclonal gammopathy (MGUS),
occasional constitutional symptoms (B symptoms), and
often depressed C1q levels. C1q level measurements
should be obtained to investigate patients for AAE-C1-
INH, especially those with new onset of angioedema
after the age of 40 years and a negative family his-
tory. C1q is nearly always normal in HAE [36]. C1q
is low in 75% of patients with AAE-C1-INH [36, 76].
C1q may be normal in AAE-C1-INH particularly in
patients taking anabolic androgens. Many patients
with AAE-C1-INH have autoantibodies that inactivate
C1-INH [13, 77–79].
Table 4 Classification of angioedema




C1-INH normal IgE mediated non-IgE mediated
Inherited Acquired Inherited Acquired
HAE-1
HAE-2







HAE-1 hereditary angioedema due to C1-Inhibitor deficiency, HAE-2 hereditary angioedema due to C1-Inhibitor dysfunction, AAE-C1-INH acquired
angioedema due to C1-Inhibitor deficiency, HAE nC1-INH hereditary angioedema with normal C1-Inhibitor levels, either due to a mutation in FXII,
ANGPTI, PLG or unknown (HAE-FXII, HAE-ANGPTI, HAE-PLG, HAE-UNK), ACEI-AE angiotensin converting enzyme inhibitor-induced angioedema
Table 5 Typical diagnostic laboratory profile of HAE-1 and
HAE-2 patients
C1-INH function C1-INH protein level C4 protein level
HAE-1 ↓ ↓ ↓
HAE-2 ↓ N/↑ ↓




We recommend that all attacks are considered for on-demand
treatment. We recommend that any attack affecting or potentially
affecting the upper airway is treated.
Evidence grade: D; Strength of recommendation: Strong, 100%
agreement.
Attacks of the upper airways can result in asphyxiation
[80, 81]. Abdominal attacks are painful and debilitating.
Peripheral attacks such as those of hands or feet result in
impaired function. All of these consequences of HAE
attacks can be minimized by on-demand treatment [82–88].
Recommendation 3
We recommend that attacks are treated as early as possible.
Evidence grade: B; Strength of recommendation: Strong, 100%
agreement.
Early treatment with C1-INH concentrate, ecallantide,
or icatibant provides a better treatment response than
late treatment. Early treatment is associated with a
shorter time to resolution of symptoms and shorter total
attack duration regardless of attack severity [89–92]. As
early treatment is facilitated by self-administration, all
patients with HAE-1/2 should be considered for home
therapy and self-administration training [6, 90, 93–95].
All C1-INH concentrates and icatibant are licensed for
self-administration, although approved product indica-
tions vary around the world.
Recommendation 4
We recommend that HAE attacks are treated with either C1-INH,
ecallantide, or icatibant. (18/20).
Evidence grade: A; Strength of recommendation: Strong, 90% agreement.
If a C1-INH concentrate, ecallantide, or icatibant are
not available, attacks should be treated with solvent
detergent-treated plasma (SDP). If SDP is not available,
then attacks should be treated with fresh frozen plasma
(FFP), where safe supply is available. We do not advise
using antifibrinolytics (e.g. tranexamic acid) or andro-
gens (e.g. danazol) for on-demand treatment of HAE at-
tacks [96], as these drugs show no or only minimal
effects when used for on-demand treatment.
Recommendation 5
We recommend that intubation or surgical airway intervention are
considered early in progressive upper airway edema.
Evidence grade: C, Strength of recommendation: Strong; 100% agreement.
The clinical course of HAE attacks is unpredictable.
Mortality due to laryngeal angioedema can occur, and
extreme caution is essential [81]. Laryngeal attacks should
be considered as medical emergencies. Rapid treatment
with an effective HAE acute medication is essential in
addition to preparing for emergency airway management
procedures if respiratory compromise develops.
Treatment with C1-INH concentrate
Treatment with plasma-derived C1-INH concentrate or
recombinant C1-INH-concentrate replaces the deficient/
dysfunctional protein in HAE-1/2 patients. Exogenous
C1-INH concentrate acts on the same targets as en-
dogenous C1-INH. Treatment results in an increase of
the plasma levels of C1-INH and helps to regulate all
cascade systems involved in the production of bradyki-
nin during attacks [88, 97–100]. One unit of C1-INH-
concentrate corresponds to the mean quantity of C1-
INH present in 1 mL fresh normal plasma.
Plasma-derived C1-INH Plasma-derived C1-INH con-
centrate (pdC1-INH) is obtained by separating C1-INH
from cryodepleted human plasma by adsorption and pre-
cipitation, purification, pasteurization, and virus filtration.
Two pdC1-INH concentrates are available for on-demand
treatment of HAE-1/2, Berinert (CSL Behring) and Cinryze
(Shire HGT). Approved product indications vary around
the world. The mean plasma half-life of pdC1-INH is longer
than 30 h [101–105]. The safety and tolerability of all
available pdC1-INH are good, and few adverse events
have been reported. The risk of allergic reactions is
negligible. Modern pdC1-INH use has not been asso-
ciated with transmission of hepatitis B nor C nor hu-
man immunodeficiency viruses [106–108].
Recombinant C1-INH Ruconest (Pharming) is the only
available recombinant human C1-INH (rhC1-INH). The
mode of action is identical to that of pdC1-INH. RhC1-
INH is indicated for on-demand treatment of all types of
HAE attacks in adults and adolescents. It is derived from
the milk of transgenic rabbits using a 3-step purification
procedure including cation exchange chromatography,
anion exchange chromatography, and affinity chromatog-
raphy. It appears that differential glycosylation of Ruconest
relative to the human protein decreases the plasma half-life
to approximately 3 h [109–111]. It is contraindicated in pa-
tients with known or suspected allergy to rabbits or rabbit-
derived products [112]. Safety data from controlled and un-
controlled studies with rhC1-INH support a favorable
safety profile. Transmission of human viruses is not a con-
cern [113–115].
Kallikrein-inhibitor
Ecallantide The kallikrein inhibitor ecallantide (Kalbitor;
Shire) is licensed only in the US for the on-demand
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treatment of all types of HAE attacks in HAE-1/2 patients
aged 12 years and older [116, 117]. Inhibition of kallikrein
activity inhibits the cleavage of high-molecular weight ki-
ninogen to bradykinin as well as the further activation of
FXIIa, halting the positive feedback mechanism leading to
additional kallikrein production. Ecallantide is a 60-amino
acid recombinant protein produced by expression in the
yeast Pichia pastoris, and has a plasma half-life of 2 h.
The main safety concern is potentially serious hypersensi-
tivity reactions, including anaphylaxis, which was reported
in 3% to 4% of treated patients. The drug, therefore,
should only be administered by a health care professional
with appropriate medical support to manage anaphylaxis
[85, 116, 118–120].
Bradykinin-receptor antagonist
Icatibant Bradykinin binds to and stimulates the
bradykinin B2 receptor, thereby mediating vasodilatation
and increased capillary permeability [121–123]. Icatibant
(Firazyr; Shire HGT), a 10-amino acid synthetic peptide, is
a specific and selective competitive antagonist of the
bradykinin B2 receptor and prevents binding of bradyki-
nin to its receptor. Icatibant is indicated for self-
administered on-demand treatment of all types of HAE at-
tacks in adults (> 18 years). It has a plasma half-life of 1 to
2 h. The safety and tolerability of icatibant are good, al-
though transient local injection site reactions (erythema,
wheal, pruritus, and burning sensation) occur. Allergic re-
actions have not been reported [84, 124, 125].
Recommendation 6
We recommend that all patients have sufficient medication for on-
demand treatment of two attacks and carry on-demand medication
at all times.
Evidence grade: D, strength of recommendation: Strong. 100% agreement.
Pre-procedural (short-term) prophylaxis
With surgical trauma, dental surgery and other
interventions associated with mechanical impact to the
upper aerodigestive tract (e.g. endotracheal intubation,
bronchoscopy or esophagogastroduodenoscopy), swellings
may occur near the site of intervention. Swellings associated
with these procedures usually occur within 48 h. Following
tooth extraction, more than one third of patients without
pre-procedural prophylaxis may develop local angioedema,
and 50% of the swellings occur within 10 h and 75% start
within 24 h [126–133]. Pre-procedural prophylaxis reduces
the risk of angioedema after above mentioned interventions.
Despite the perceived benefits of pre-procedural prophy-
laxis with C1-INH concentrate, evidence for its efficacy is
scarce. Case reports and series suggest that despite prophy-
laxis, swellings may occur even after relatively minor proce-
dures [127, 132]. However, several reports document a
reduction in the incidence of swelling for both adults and
children with preprocedural prophylaxis, and the response
appears to be dose related [126, 127, 134, 135]. Preproce-
dural prophylaxis with C1-INH concentrate is therefore
recommended for all medical, surgical and dental proce-
dures associated with any mechanical impact to the upper
aerodigestive tract.
Recommendation 7
We recommend short-term prophylaxis before procedures that can
induce an attack.
Evidence grade: C, strength of recommendation: Strong. 100%
agreement.
C1-INH concentrate should be used for pre-
procedural prophylaxis, as close as possible to the
start of the procedure. Dosage has yet to be fully
established. Product approved indication may vary by
country [136, 137]. Most experts use either 1000 units
or a dose of 20 units/kg of pdC1-INH. Fresh frozen
plasma (FFP) may be used for short-term prophylaxis
and on-demand therapy, but is not as safe as C1-INH
concentrate and is a second-line agent because of the
greater risk of blood borne disease transmission, and
allosensitization. [2–5, 9, 134].
Attenuated androgens (e.g. danazol) have been
recommended in the past for pre-procedural prophylaxis
as an alternative to C1-INH concentrates [134]. Pre-
procedural prophylaxis with attenuated androgens is even
considered to be safe in children, but C1-INH concentrate
is considered the prophylaxis of choice [127]. Very fre-
quent short courses may lead to side effects associated
with long-term use. For scheduled pre-procedural prophy-
laxis, androgens are used for 5 days before and 2 to 3 days
post event. Tranexamic acid (TA) has been used for pre-
procedural prophylaxis in the past, but is not recom-
mended by most experts in attendance at the guideline
meeting [2–5, 127, 134].
With all pre-procedural prophylactic treatments,
break-through attacks can occur, so patients should re-
main under observation, and on demand treatment
needs to be available [2–5, 126, 127, 129].
Long-term Prophylaxis (LTP)
Long-term prophylaxis of HAE refers to the use of
regular medication to reduce the burden of the disease
by preventing/attenuating attacks in patients with
confirmed HAE-1/2. Long-term prophylaxis should be
individualized, and considered in all severely symptom-
atic HAE-1/2 patients taking into consideration the ac-
tivity of the disease, frequency of attacks, patient’s
quality of life, availability of health-care resources, and
failure to achieve adequate control by appropriate on-
demand therapy. As all of these factors can vary over
time, all patients should be evaluated for long-term
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prophylaxis at every visit, at least once a year. Successful
long-term prophylaxis requires a high degree of compli-
ance; therefore the patient’s preferences should be taken
into consideration. Patients with ongoing long-term
prophylaxis should be assessed regularly for efficacy
and safety of the therapy, and dosage and/or treatment
interval should be adapted according to the clinical re-
sponse. Upper airway edema and other attacks may
occur despite the use of long-term prophylaxis. There-
fore, all patients using long-term prophylaxis should
also have on-demand medication (C1-INH concentrate,
ecallantide, or icatibant) as per recommendation 6
[1, 2, 4, 5, 61, 138–140].
Recommendation 8
We recommend prophylaxis be considered for patients who face events
in life that are associated with increased disease activity.
Grade of evidence: D, strength of recommendation: Strong, ≥ 90
agreement.
Recommendation 9
We recommend that patients are evaluated for long-term prophylaxis at
every visit. Disease burden and patient preference should be taken into
consideration.
Grade of evidence: D, strength of recommendation: Strong, 100%
agreement.
Plasma-derived C1-INH
Plasma-derived C1-INH is currently the preferred long-
term prophylaxis for the prevention of HAE attacks.
Approved product indications vary around the world.
Dosing should be twice a week based upon the half-life
of pdC1-INH. Dose and/or frequency may need adjust-
ment for optimum efficacy [86, 141].
Recent studies show that subcutaneous twice-weekly
administration of pdC1-INH at doses of 40 U per
kilogram or 60 U per kilogram bodyweight provided
very good and dose-dependent preventive effects on
the occurrence of HAE attacks [142]. The subcutane-
ous route may provide more convenient administra-
tion as well as maintain improved steady-state plasma
concentrations of C1INH compared to IV C1INH
prophylaxis.
Appropriate vaccination for hepatitis A and B
should be generally considered for patients in regular/
repeated administration of human plasma-derived
products [86, 143–146]. Routine prophylaxis with
pdC1-INH has been shown to be safe and effective,
and it improves quality of life in patients with rela-
tively frequent HAE attacks compared with acute
treatment of individual HAE attacks [86, 143–145].
Thromboembolic events due to C1-INH concentrate
use in HAE are rare, and patients who experience
such events often have underlying thromboembolic
risk factors (e.g. implanted central venous catheters
[147–151]. There are no known interactions with other
medicinal products. Tachyphylaxis seems rare with only
one report of increasing doses required to prevent attacks
when C1-INH concentrate is used regularly for prophy-
laxis [152].
Recommendation 10
We recommend use of C1-Inhibitor for first line long term prophylaxis.
Grade of evidence: A, strength of recommendation: Strong, 50–75%
agreement (majority vote).
Recommendation 11
We suggest to use androgens as second-line long-term prophylaxis.
Grade of evidence: C, strength of recommendation: Weak, 50–75%
agreement (majority vote).
Recommendation 12
We suggest adaptation of long-term prophylaxis in terms of dosage
and/or treatment interval as needed to minimize burden of disease.
Grade of evidence: D, strength of recommendation: Weak, 100%
agreement.
Androgens
Attenuated androgens are traditionally used for long-
term prophylaxis of HAE-1/2 [153–162]. Androgen
derivatives have been demonstrated to be effective in
HAE-1/2, and the oral administration facilitates their
use [154, 156, 158]. However, androgens must be
regarded critically, especially in light of their adverse
androgenic and anabolic effects, drug interactions,
and contraindications. Side effects are numerous and
involve the majority of patients; in other words, the
absence of side effects is exceptional [156, 163]. Side
effects appear to be dose related. Virilization is the
most feared complication in women; menstrual disor-
ders and even amenorrhea as well as diminished li-
bido and hirsutism are also common [164], as are
weight gain, headache, myalgia, depression, and acne.
Androgens may lead to virilization of the female fetus
and are, therefore, absolutely contraindicated during
pregnancy [165, 166]. In children and adolescents,
therapy with androgens may interfere with the natural
growth and maturation process. In addition, andro-
gens are subject to numerous contraindications and
show interactions with many other drugs (e.g. statins).
Careful surveillance is imperative in long-term
prophylaxis with androgens. In addition to clinical
tests and examinations and questioning of the patient,
semiannual blood and urine tests (standard urine test
strip) are needed, and at least once a year, an ultra-
sound of the liver should be performed. It is unclear
if stopping long term prophylaxis with attenuated an-
drogens should be done by tapering off gradually over
time [167, 168].
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The dose of androgens needed to control HAE attacks
can vary between the equivalent of 100 mg every other
day and 200 mg of danazol 3 times a day. The minimal
effective dose should be used. Dosages above 200 mg
of danazol daily for extended periods of time are not
recommended, because of side effects. The response to
androgens varies considerably, and the dose required
for long-term prophylaxis is variable. For this reason,
the dosage should be adjusted according to clinical
response and not adjusted based on C4 and C1-INH
results [2, 4, 5, 10].
Anti-fibrinolytics
Antifibrinolytics are not recommended for long-term
prophylaxis. Data for their efficacy are largely lacking,
but some patients may find them helpful. They are
primarily used when C1-INH concentrate is not avail-
able and androgens are contraindicated. Side effects
are usually minor. They include gastrointestinal up-
sets (can be reduced by taking the drug with food),
myalgia/creatine kinase elevation, and a theoretical
risk of thrombosis. Contraindications/precautions in-
clude the presence of thrombophilia or increased
thrombotic risk or acute thrombosis, e.g. deep ven-
ous thrombosis, pulmonary embolism. The doses of
Tranexamic Acid (TA) used range from 30 to 50 mg/kg to
6 g daily. Dose ranging studies and comparisons with
other prophylactic medications have not been performed
[2, 4, 5, 9, 84, 169–171].
Management of HAE-1/2 in children
Course of disease and clinical picture
The gene defect (SERPING1 mutation) of HAE-1/2 is
already present at birth, but symptoms are uncom-
mon during neonatal age or infancy. The symptoms
may occur at any age, but usually begin in childhood
or adolescence. The median age of symptom onset is
approximately 12 years of age. At the age of 12 years,
50% of all female patients are symptomatic and at
the age of 23 years, 90% are symptomatic. In males,
50% are symptomatic by the age of 13 years and 90%
by the age of 25 [172]. Subcutaneous edema is the
most common and the earliest symptom. However,
abdominal symptoms may be an unrecognized and
often overlooked symptom of HAE-1/2 in infancy.
Asphyxia may ensue rapidly in children, probably be-
cause of smaller airway diameter [80]. The earliest
occurrence was described in a 4-week-old boy [173].
Estimating the prevalence of abdominal attacks in
the pediatric population is difficult as abdominal pain
is common in childhood. The frequency and the
severity of symptoms may increase during puberty
and adolescence. The earlier the onset of symptoms,
the more severe the subsequent course of HAE-1/2
[174, 175]. Erythema marginatum as a prodromal
sign is more frequent in the pediatric population. It
has been observed in 42% to 58% of cases and is
often mistaken for urticaria. Misdiagnosis of pro-
dromal erythema marginatum can lead to incorrect or
insufficient treatment [9, 15, 62, 102, 169, 176–180].
Diagnosis
With autosomal dominant inheritance, the offspring of a
patient with HAE-1/2 stands a 50% chance of inheriting
the disease. Therefore, it is important to establish the
diagnosis as early as possible, ideally before the onset of
clinical manifestations. Until a full investigation for
HAE-1/2 is complete, all offspring should be considered
to have HAE-1/2.
Recommendation 13
We recommend testing children from HAE-affected families be done
as soon as possible and all offspring of an affected parent be
tested.
Evidence grade: D, strength of recommendation: Strong, 100%
agreement.
Complement concentrations measured in umbilical
cord blood of full-term neonates are lower than maternal
levels. Antigenic and functional C1-INH levels correspond
to 70% and 62% of adult values respectively [15, 181, 182].
Therefore, using umbilical cord blood for complement
measurements may produce false positive (low) results.
The assessment of complement in peripheral venous
blood (serum/plasma) in children lacks reference values.
However, with exceptions, in HAE 1/2 aged less than
1 year, C1-INH antigenic level and/or functional activity
are low [59, 183]. The measurement of C4, however, was
found not to be useful for diagnosing of HAE-1/2 in chil-
dren below the age of 12 month, as C4 levels are fre-
quently low in healthy infants [59, 183]. Genetic testing
increases the diagnostic reliability in children and may be
helpful in cases in which biochemical measurements are
inconclusive and the genetic mutation of the parent is
known [15, 59, 183]. All early complement testing per-
formed in offspring of HAE-1/2 patients should be re-
peated after the age of 1 year [9, 15, 59, 183, 184].
Prenatal diagnosis of HAE-1/2 has not become wide-
spread in clinical practice. Reasons include (1) mutations
in affected parent C1-INH gene are not detected in 8%
to 10% of cases, (2) identical mutations may be associ-
ated with substantially different phenotypes, and (3) ad-
vances in therapy have significantly improved quality of
life of patients with HAE-1/2 [9, 40, 185, 186].
Measurements of C1-INH antigen (protein) level, C1-
INH functional (activity) level, and C4 level are advisable
in all children with angioedema without urticaria.
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Therapy
Similar to adults, all pediatric HAE-1/2 patients need to
have a treatment action plan (see below) and on-
demand therapy.
Recommendation 14
We recommend C1-INH be used for treatment of HAE attacks in children
under the age of 12.
Evidence grade: C, strength of recommendation: strong, > 90%
agreement.
On-demand treatment
Plasma-derived C1-INH concentrate is the only ap-
proved drug for HAE-1/2 on-demand treatment in
childhood [15]. Treatment with pdC1-INH concentrate
is effective, well tolerated and shows a good safety pro-
file in pediatric patients. During abdominal attacks, par-
enteral fluid replacement may be required in view of the
increased susceptibility of children to hypovolemia and
dehydration, because extravasation into the peritoneal
cavity and the intestinal lumen can be substantial. When
pdC1-INH concentrate is not available SDP is preferred
over FFP, but both are considered second-line treatment.
Recombinant C1-INH and ecallantide are licensed for
the use in adolescents in some countries. In 2017, icati-
bant was licensed for the use in children or adolescents
in some countries. Clinical trials to investigate the effi-
cacy and safety of rhC1-INH and icatibant in children
are ongoing [12, 15, 102, 177, 180, 187–190].
Pre-procedural prophylaxis
As in adults, pre-procedural prophylaxis is recom-
mended for medical, surgical and dental procedures as-
sociated with any mechanical impact to the upper
aerodigestive tract [126, 127]. Plasma-derived C1-INH is
the first-line pre-procedural option, but short courses of
attenuated androgens can be used as second line when
C1-INH concentrate is not available. With either option,
on-demand therapy should be available because short-
term prophylaxis is not 100% effective.
Long-term prophylaxis
The indications for long-term prophylaxis in adolescents
are the same as in adults (see above). The preferred ther-
apy for long-term prophylaxis is pdC1-INH. The dosing
interval and dose may need to be adjusted according to
the individual response.
When C1-INH concentrate is not available for long-
term prophylaxis, antifibrinolytics (i.e. Tranexamic acid
20–40 mg/kg) are preferred to androgens because of
their better safety profile; however, efficacy is questioned
by many, and data are not available supporting its use.
Epsilon aminocaproic acid is less well tolerated than
tranexamic acid. Androgens are not recommended for
long-term prophylaxis in children and adolescents prior
to Tanner Stage V, however, long-term use has been re-
ported, and in some cases, the benefits may outweigh
the risks. The administration of androgens requires care-
ful safety monitoring. The continued need for regular
prophylaxis with androgens and the dosing should be
reviewed on a regular basis. Initial danazol dose for chil-
dren is 2.5 mg/kg per day with subsequent adjustment,
until symptom suppression or the maximum tolerated
or maximum recommended dose is reached, with a
maximum single dose of 200 mg per day. Androgens re-
sult in masculinization and hypogonadism in boys and
menstruation irregularities in girls. Unfavourable effects
on behaviour are possible. Reduction in ultimate body
height may occur owing to the premature closure of epi-
physeal growth plates [2–5, 10, 12, 15, 180, 191, 192].
Primary prevention
As in adults, most attacks in children occur without a
obvious trigger [193]. Infections and mechanical trauma
seem to be more common trigger factors during
childhood. Compulsory and recommended vaccinations
for children are safe and the prevention of infections
may reduce the frequency of attacks (i.e. throat
infections). Medicinal products, which can cause edema
as an adverse effect are less frequently used in children.
Treatment with ACE-I is less often necessary during
childhood. However, early initiation of oral estrogen
containing contraceptives is increasingly common and
may trigger attacks. These agents should be avoided.
Hormonal contraception with progesterone-only pills
may turn out to be beneficial for many young women
with HAE-1/2 [9, 194, 195], or at least should not in-
crease attack frequency. Other triggers like strenuous
physical activities involving mechanical trauma and
emotional challenges (stress) are essential elements of
childhood and adolescence [193]. Restrictions of sus-
pected triggers will result in a restriction of activities
and lifestyle, and should, therefore, be individualized and
sensibly applied. The aim of HAE-1/2 management at all
ages should be to normalize life activities and lifestyle
whenever possible [15].
Other management considerations
Providing pediatric patients and their families with
appropriate information is indispensable to support
them to adopt a suitable lifestyle and to avoid
complications. Educators, teachers, and health care
personnel responsible for the child at daycare or school
should receive written information on the disease, with
advice on management of HAE attacks, including the
urgency of treatment for airway attacks. C1-INH con-
centrate for emergency use should be available at home,
Maurer et al. World Allergy Organization Journal  (2018) 11:5 Page 11 of 20
school, and travel including school field trips. As noted
above, an action plan is necessary and the family and
local hospital should have therapies available for emer-
gency treatment and this should be included in the treat-
ment plan. All HAE patients have a potential for
receiving human blood products. Because of this, HAE
patients should be screened for hepatitis B and C and
HIV. Vaccinations for hepatitis A and B are recom-
mended by many experts [15, 177]. All patients should
be considered to receive influenza vaccine and other
routine vaccinations.
Management of HAE-1/2 during pregnancy and
lactation
Course of disease and clinical picture
The anatomical, physiological and hormonal changes
during pregnancy may influence the manifestations and
affect the course and treatment of HAE-1/2. Pregnancy
can mitigate, aggravate, or have no effect. Infrequently,
the manifestations of HAE-1/2 first occur during preg-
nancy [196–198]. Attack frequency observed during
previous pregnancies is only in part predictive of that
in subsequent pregnancies [9, 196, 198]. Pregnant
HAE-1/2 patients require vigilant care and meticulous
monitoring by an HAE expert. Patients should be
managed in close cooperation by professionals from
relevant medical specialties. Labour and delivery only
rarely induce an attack, which may occur either during
labour or within 48 h of delivery. Close follow-up is
recommended for at least 72 h postpartum after uncom-
plicated vaginal delivery. Breastfeeding may be associated
with an increased number of maternal attacks, with
abdominal symptoms and facial edema, but is still recom-
mended based on benefits provided to the infant [9, 196,
197, 199]. Care for C-section, especially if intubation is
necessary, should proceed as in any other surgical
procedure performed on a patient with HAE-1/2 and
is covered below.
Diagnosis
In healthy women, the plasma levels of C1-INH decrease
during pregnancy, and return to normal after delivery
[200, 201]. Therefore, measurements of levels of C1-
INH function, C1-INH protein and C4 for the purpose
of diagnosing HAE-1/2 during pregnancy should be
interpreted with caution. It is recommended to repeat
the measurements after childbirth to confirm the diag-
nosis of HAE [9, 199].
Therapy
C1-INH concentrate is recommended as first-line therapy
for pregnant or breast-feeding HAE-1/2 patients as it is safe
and effective [202]. No published experience is available for
ecallantide. Although contraindicated by label, there are
isolated case reports about the administration of icatibant
during pregnancy with no maternal or fetal adverse effects
reported [203–205]. SDP may be used when C1-INH con-
centrate is not available and fresh frozen plasma when SDP
is not available [196–198, 206–210].
Recommendation 15
We recommend C1-INH as the preferred therapy for HAE attacks during
pregnancy and lactation.
Evidence grade: D, strength of recommendation: strong, 100%
agreement.
Pre-procedural prophylaxis is recommended,
preferably with C1-INH concentrate, before any inter-
vention such as chorionic villus sampling, amniocentesis,
and induced surgical abortion. Alternatively, C1-INH
concentrate should be available and administered im-
mediately at the onset of an attack. It is recom-
mended to manage childbirth in the hospital setting,
unless robust measures for prompt treatment HAE at-
tacks are available. Although mechanical trauma and
stress are known to trigger attacks, few women have
developed angioedema during labour and delivery [9,
198]. Therefore, routine administration of pre-procedural
prophylaxis before uncomplicated natural delivery is
not mandatory, but C1-INH concentrate should be
immediately available for on-demand use. However,
administering C1-INH concentrate as pre-procedural
prophylaxis is recommended before labour and delivery
when symptoms have been recurring frequently during
the third trimester and the patient’s history includes
genital edema caused by mechanical trauma, during
forceps delivery or vacuum extraction. Vaginal delivery
is preferred because surgery or general anaesthesia
may involve endotracheal intubation. Pre-procedural
prophylaxis with C1-INH concentrate and epidural
anaesthesia is recommended before a caesarean section,
and intubation should be avoided if possible. If intu-
bation is required, pre-procedural prophylaxis is
mandatory [2–5, 9, 10].
LTP may become indicated during pregnancy, especially
in women experiencing an increase of attack frequency. In
these women, C1-INH concentrate is considered a safe
and effective treatment option [197]. Antifibrinolytics may
be considered if C1-INH concentrate is unavailable, but
efficacy is not proven [9, 209, 211].
Androgens are contraindicated, as these drugs cross the
placenta. Their adverse effects include masculinization of
the female fetus, placental insufficiency, and fetal growth
retardation. Breast-feeding should be discontinued before
androgens are introduced. Terminating lactation itself
may reduce attack frequency [165, 166].
Plasma-derived C1-INH concentrate is considered
the best therapy for on-demand treatment, short-term
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prophylaxis and long-term prophylaxis when indicated
during lactation. Androgens and antifibrinolytics are
secreted in breast milk. In contrast to androgens,
tranexamic acid was found to be safe during breast-
feeding [212].
Patient support, home therapy and self-
administration, and other management
considerations
Patient support
Patient organizations and support groups provide help
and support for HAE patients, caregivers, and family
members. They endorse the philosophy that all
patients worldwide should have sufficient resources to
control their HAE symptoms and fulfil their potential
at school, at work, and in their relationships. HAEi,
the international umbrella organization for the world’s
Hereditary Angioedema (HAE) patient groups, and
national HAE associations have active informative
web sites for patients and health care providers. HAEi
has launched a “call to action” aimed at increasing
the awareness and knowledge on HAE with governments,
health authorities, and health care professionals and to
achieve recognition of HAE as a serious, disabling,
potentially life-threatening, and chronic condition that
must receive timely accurate diagnosis and effective
treatment.
Patient organizations also work toward identifying
and addressing unmet needs in HAE management,
which include the development of safe and well-
tolerated new prophylactic and on-demand therapies,
the optimization of existing long-term prophylactic
and on-demand therapies (e.g., by dose-ranging stud-
ies, paediatric studies), increasing the availability of
modern treatment options worldwide, emphasizing
the need for self-care, individual action plans, early
therapy, and gene therapy research. As with most
diseases, information obtained from the internet is
not always accurate and reliable; however, HAEi pro-
vides reviewed, updated, and scientifically sound in-
formation and is considered to be a quality source
for patient education.
Individualized patient action and treatment plans
Because HAE-1/2 is an unpredictable, painful, and
life-threatening condition that incurs a huge stressful
burden on patients and their families, an individual-
ized treatment plan should be carefully developed in
partnership between the physician and each patient.
Individualized treatment plans should address prevent-
ive measures and home care and self-administration.
It should include an effective emergency (on-demand)
treatment plan, with clear instructions on how to best
use medications to treat HAE attacks. Patients should
carry on-demand medication and an HAE identifica-
tion card with instructions on how to manage an
HAE attack. Patients on long-term prophylaxis also
require an action plan and available therapy for on-
demand use [213–216].
Recommendation 16
We recommend that all patients have an action plan.
Evidence grade: D, strength of recommendation: Strong, 100%
agreement.
Recommendation 17
We suggest that HAE specific comprehensive, integrated care is
available for all patients.
Evidence grade: D, strength of recommendation: Weak, 100%
agreement.
Home therapy and self-administration
Self-administration is crucial for an effective on-
demand therapy as early treatment in the course of
an attack has been shown to be more effective and
may prevent complications. This effect is independ-
ent of the on-demand medication used (see recom-
mendation 3 and text) and facilitated by the skill of
the self-administrator or home therapy partner [6,
90, 93–95]. Similarly, self-administration facilitates
long-term prophylaxis. Every patient should be con-
sidered for home therapy and self-administration.
Having to attend a medical facility to receive acute
medication may result in delayed on-demand treat-
ment, prolonged observation or inappropriate ther-
apy. Self-administration training should include a
home therapy partner (family member or friend who
can provide support, advice, and administration of
therapy when the patient is compromised or unable
or uncomfortable with self-treatment. Home therapy
decreases the severity and duration of HAE attacks,
reduces morbidity and disability, and can improve
quality of life and productivity. In addition, the cost
of care is reduced considerably by the use of home
and self-therapy [6, 139, 189, 215, 217–223].
C1-INH concentrate home therapy is also suitable for
children with frequent or disruptive attacks, where a
responsible adult is available and willing to undertake
training. Experience with hemophilia suggests that it is
beneficial for children to be encouraged to take an active
part early in their treatment, and even at the age of 8, IV
self-administration has been proven possible and safe
[189, 224]. Advanced age is not a contraindication for
home therapy, provided that patients and/or home therapy
partners can safely and effectively administer the treatment.
The subcutaneous route may provide more convenient ad-
ministration in all age groups covered by the license. As
pdC1-INH concentrate is a blood derivative, tracking for
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home use is important in the event of recall, as well as to
make sure that the product is being used as directed.
Recommendation 18
We recommend that all patients who are provided with on-demand treat-
ment licensed for self-administration should be taught to self-administer.
Evidence grade: C, strength of recommendation: Strong, 100% agreement.
Early treatment is crucial in cases of upper airway
involvement (tongue, uvula, larynx). Patients should self-
administer treatment while awaiting transfer to hospital. It
is extremely important to encourage all patients to seek
further care immediately after administration of therapy.
Upper airway swelling may progress or rebound, and re-
peat dosing may be necessary. Seeking emergency care
after therapy is essential to reduce the risk of suffocation.
Avoidance of triggers
A variety of conditions and events are known to trigger
HAE attacks. Trauma, whether accidental or associated
with dental, medical, and surgical procedures, may result in
a swelling attack. The use of estrogen-containing oral
contraceptive agents and hormone replacement therapy
may trigger attacks. These agents should be avoided. Hor-
monal contraception with progesterone-only pills may turn
out to be beneficial for many women with HAE-1/2 [9, 194,
195]. Antihypertensive agents containing ACE inhibitors
may increase the frequency or precipitate HAE attacks and
should therefore be avoided strictly.
Other reported triggers include psychological stress,
fatigue, febrile illness, possibly Helicobacter pylori infection,
and the menstrual cycle. Patients should be made aware of
potentially relevant triggers of symptoms to reduce
precipitation of attacks. Many of these latter triggers are
only suspected triggers and of limited significance. Most
attacks in most patients are unpredictable. Therefore,
physicians should not support excessive avoidance of
suspected triggers, in order not to limit the patient’s normal
life. Influenza vaccine may reduce upper airway infections
and possibly reduce upper airway swelling. Good dental
care can reduce extractions, need for aggressive dental
procedures, and prevent acute or chronic intraoral
inflammation, which might reduce the threshold for
attacks. Monitoring for side effects of medications is
important and is outlined above [129, 130, 193, 225–227].
Recommendation 19
We recommend that all patients with HAE should be educated about
possible triggers which may induce HAE attacks.
Evidence grade: C, strength of recommendation: strong, 100% agreement.
Expert involvement and follow-up
HAE-1/2 patients are encouraged to find a health care
provider with knowledge and interest in the disease.
When and where possible, care should be provided by
comprehensive care clinics with expertise in HAE.
It is recommended that HAE patients have a
medical evaluation at least annually. Newly diagnosed
patients and those on long-term prophylaxis with
attenuated androgens should be seen in a shorter
interval. Those on androgens should continue to be
seen twice a year. Evaluation at follow-up visits
should include recording of type and frequency and
severity of symptoms, frequency of use, and effective-
ness of treatments for swelling attacks. A physical
examination and appropriate laboratory evaluation
should be conducted [228, 229].
Family screening
HAE-1/2 is a genetic disorder with autosomal dominant
transmission. Family members including grandparents,
parents, siblings, children, and grandchildren of HAE-1/2
patients should be screened for C1-INH function, C1-INH
protein, and C4 plasma levels. Delayed diagnosis leads to
morbidity and decreased quality of life due to delayed intro-
duction of appropriate therapy. There is a risk that the first
HAE attack might affect the airway and could be fatal.
Recommendation 20
We recommend that family members of individuals with HAE should
be screened for the condition based on.
-autosomal dominant inheritance.
-delayed diagnosis leads to morbidity and decreased quality of life
without appropriate therapy.
-risk of the first angioedema event being fatal due to airway
involvement without appropriate therapy.
Evidence grade: D, strength of recommendation: strong, 100%
agreement.
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